Skip to main content
Premium Trial:

Request an Annual Quote

HistoRx Raises $1.5M in Series A Financing

NEW YORK, Sept. 14 (GenomeWeb News) - HistoRx, a provider of imaging technology for tissue and tissue microarrays, has raised $1.5 million in a Series A financing round, the company said today.

 

HistoRx, based in New Haven, Conn., exclusively licenses the imaging technology from YaleUniversity, where it was developed by David Rimm and Robert Camp. The technology allows users to measure protein expression in subcellular compartments automatically. The company also holds an exclusive license to patient cohort databases from Yale's tissue archive containing clinical follow-up information corresponding to different types of human cancer.

 

HistoRx provides contract services to academic institutions and companies and licenses its technology to selected laboratories.

 

Navigator Technology Ventures led the investment round, which also included Genentech, Sachem Ventures, and Marnat Investments.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.